Working Night Shifts Is Associated with Sleep Disorders, Study Finds
December 13th 2023Late shift work is associated with sleep disorders the most for females, the age group <30 years old, people who live alone or with roommates, have only up to an elementary or secondary education, and people who work the night shift.
Read More
Study Shows Promise of Guizhi-Shaoyao-Zhimu Decoction Helping Gout
December 13th 2023Guizhi-Shaoyao-Zhimu Decoction treatment helps lower levels of blood uric acid, c-reactive proteins, erythrocyte sedimentation rate, interleukin 6, interleukin 8, tumor necrosis factor, and visual analogue scale more than conventional treatment for gout.
Read More
Sickle Cell Disease with Venous Thromboembolism Linked to Higher Mortality
December 12th 2023Presented at ASH 2023, findings of a new study showed patients with sickle cell disease and venous thromboembolism have longitudinal worsening of left ventricular diastolic and right-sided cardiac function.
Read More
mRNA Gene Therapy is More Cost-Efficient for Treating Inherited Retinal Diseases
December 7th 2023Gene therapy with mRNA is more cost-efficient, has a better safety profile, and is more reproducible than the viral vector, AAV, currently used for gene therapy to improve inherited retinal diseases.
Read More
Pooled Analysis Supports Bioequivalence Between MB02 and Reference Bevacizumab
December 5th 2023In a new pooled analysis of 3 pharmacokinetic studies, the investigators confirmed the bioequivalence, safety, and immunogenicity between biosimilar MB02 and European Union approved bevacizumab and US-approved bevacizumab.
Read More
Patients Unsatisfied After Mandatory Adalimumab Biosimilar Transition
December 5th 2023Aotearoa, New Zealand had a mandatory adalimumab biosimilar transition from March – September 2022. A survey reveals low satisfaction with biosimilar’s quality, as well as the lack of alcoholic wipes and a support program.
Read More
CBT Linked to Improving Depression Symptoms in Adults with Type 1 Diabetes
December 4th 2023In a new study focusing on adults with type 1 diabetes and mild-moderate depressive symptomatology, a CBT program helped depression symptoms, quality of life, anxiety, treatment adherence, and total diabetes-related stress in emotional, physical, and impersonal subscales.
Read More
Mothers’ Mental Disorders Is Not Linked to Type 1 Diabetes in Offspring
December 4th 2023Mothers with mood disorders—either bipolar disorder, major depressive disorder— or schizophrenia/ schizoaffective disorder are not associated with their offspring’s risk for type 1 diabetes. Results suggest mothers with bipolar disorder tend to develop type 1 diabetes, but data is not clinically significant.
Read More
Lower Sleep Efficiency Linked to Higher HbA1c in Adolescents with Type 1 Diabetes
December 2nd 2023The study did not find an association between glycemic parameters and flow-mediated dilation, but they did find associations between lower sleep efficiency with poorer glycemic control, insulin resistance, estimated glucose disposal rate, and HbA1C.
Read More
FDA Accepts Xanomeline-Trospium Drug Application for Schizophrenia Treatment
November 29th 2023The FDA will decide on the approval of xanomeline-trospium, a dual M1/M4 muscarinic acetylcholine receptor agonist in the central nervous system, for the treatment of schizophrenia patients by September 2024.
Read More
In a new study, the highest socioeconomic group was associated with lower morality rates for all-cause mortality, lower morality from natural causes, and higher mortality from external causes. Although the data does not show a significant link between the role of socioeconomic position with the mortality rate among people with mental disorders.
Read More
COVID-19 Vaccine Safe for Patients with Hepatitis C Virus-Related Liver Disease
November 22nd 2023After receiving the COVID-19 vaccination, the antibody titers of patients with cirrhosis and hepatocellular carcinoma were significantly reduced compared to patients with chronic hepatitis C patients.
Read More